Precision medication emphasizes tailored treatment approaches based on individual patient characteristics, yet the limitations in current drug target identification hinder therapeutic advancements.

This review aims to explore innovative strategies for identifying druggable targets (a biological target that is known to or is predicted to bind with high affinity to a drug) and enhancing their therapeutic potential within the framework of precision medication.

We examine various methodologies employed to assess the targets’ abilities in forming drugs, including computational modeling, network analysis, and multi-omics integration. Recent technological advancements in machine learning facilitate the extraction of relevant features from large datasets, improving target prioritization.

Despite existing challenges in the landscape of targeted therapies—such as limited targets and high clinical failure rates—emerging data-driven approaches show promise in refining the drug discovery process. Enhanced validation frameworks are essential to mitigate risks associated with inadequate target assessment during early discovery phases.

The identification of viable druggable targets is critical for advancing personalized treatment options. By integrating diverse biological datasets and employing cutting-edge predictive tools, researchers can streamline drug development pathways, ultimately leading to more effective therapeutic interventions tailored to specific patient populations. This review highlights the need for innovative strategies in drug target discovery to unlock the full potential of precision medicine.